What diagnostic tests are recommended as the initial work‑up for a man with suspected benign prostatic hyperplasia (BPH)?

Initial Diagnostic Work-Up for Suspected BPH

The American Urological Association recommends a core initial evaluation consisting of: medical history, AUA Symptom Index (IPSS), digital rectal examination, urinalysis, and selective PSA testing for men with ≥10-year life expectancy. 1

Mandatory Initial Tests

Medical History

• Obtain detailed history focusing on: onset and duration of urinary symptoms (both obstructive and irritative), previous urologic surgeries, current medications that may affect voiding, comorbid conditions affecting bladder function, and family history of prostate disease including cancer 1

AUA Symptom Index (IPSS)

• Use the AUA Symptom Index—identical to the seven symptom questions of the IPSS—to quantify symptom severity (mild: 0-7, moderate: 8-19, severe: 20-35) 2, 1
• The IPSS assesses seven symptoms: incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia 2
• Include the disease-specific quality of life question to determine how bothersome symptoms are to the patient—this is critical because a moderately symptomatic but highly bothered patient may warrant intervention more than a severely symptomatic patient who tolerates symptoms well 2, 1

Digital Rectal Examination

• Perform DRE to assess prostate size, consistency, and nodularity, and to exclude locally advanced prostate cancer 1
• Include a focused neurologic examination to rule out neurogenic bladder 1

Urinalysis

• Perform dipstick or microscopic urinalysis to screen for hematuria and urinary tract infection 1

PSA Testing (Selective)

• Offer PSA testing to men with ≥10-year life expectancy when knowledge of prostate cancer would change management, or when PSA may influence voiding symptom management 1
• Be aware that approximately 25% of men with BPH have PSA >4 ng/mL due to benign enlargement alone 1

Optional Tests (Reserved for Specific Scenarios)

Uroflowmetry and Post-Void Residual

• Not required for initiating watchful waiting or medical therapy 1
• Consider when: initial evaluation suggests non-prostatic cause of symptoms, patient selects invasive therapy, or results would change management 1
• Men with maximum flow rate (Qmax) <10 mL/sec are more likely to have urodynamic obstruction and improve with surgery 1
• Large PVR volumes (e.g., 350 mL) may indicate bladder dysfunction and potentially herald disease progression, but PVR is not a contraindication to conservative or medical management 1

Prostate Ultrasound

• Appropriate when minimally invasive or surgical interventions are chosen, to assess prostate volume, intravesical prostatic protrusion, and presence of intravesical lobes that may impact surgical approach 1
• Not routinely necessary for watchful waiting or medical therapy 1

Urethrocystoscopy

• Only appropriate when specific risk factors are present: history of hematuria (microscopic or gross), urethral stricture or risk factors (prior urethritis/urethral injury), bladder cancer history, or prior lower urinary tract surgery 3
• Should not be used in routine initial evaluation or solely to determine need for treatment 3
• Cystoscopy is optional before invasive therapy and may guide therapy selection based on prostatic anatomy (lateral versus middle lobes) 3

Urine Cytology

• Consider in men with predominantly irritative symptoms, especially with smoking history or other bladder cancer risk factors 1

Pressure-Flow Studies

• Optional before invasive therapy, particularly for men with flow rates >10 mL/sec when surgery is considered, or in those with neurological conditions affecting bladder function 1

Tests NOT Recommended

Serum Creatinine

• Routine measurement is not indicated in initial evaluation, as baseline renal insufficiency is no more common in men with BPH than in the general population 1

Upper Urinary Tract Imaging

• Not recommended unless the patient has hematuria, UTI, renal insufficiency, or history of urolithiasis or urinary tract surgery 1

Critical Pitfalls to Avoid

• Do not rely on symptom scores alone to determine need for intervention—always assess how bothersome symptoms are to the individual patient 2, 1
• Do not order uroflowmetry before starting alpha-blockers, as symptom response is not dependent on baseline flow rate 1
• Do not withhold treatment based solely on elevated PVR, as many patients maintain large residual volumes without complications 1
• Do not perform cystoscopy as part of routine initial evaluation in patients without specific risk factors—it adds unnecessary cost and invasiveness 3